Dev-Res-Prog-001
开发-研究-Prog-001
基本信息
- 批准号:10245096
- 负责人:
- 金额:$ 8.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-19 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AwardBrain NeoplasmsCancer CenterCommunicationDataDevelopmentFundingFutureGliomaGoalsInfrastructureInstitutionMeasuresMonitorOutcomePatientsPilot ProjectsProcessProgram Research Project GrantsProgress ReportsRequest for ProposalsResearchResearch Project GrantsScientistexperienceinnovationprogramstargeted treatment
项目摘要
The objective of the Glioma SPORE Developmental Research Program (DRP) is to identify innovative pilot
research projects in glioma that have translational potential. The DRP utilizes a solicitation and review process
to select meritorious pilot projects for funding. The solicitation process capitalizes on an established, extensive
Dana-Farber/Harvard Cancer Center (DF/HCC) communications infrastructure to widely disseminate an annual
Request for Proposals (RFP). The review process utilizes an experienced panel of DF/HCC glioma scientists.
The DRP provides limited-duration funding for innovative projects that have ultimate translational potential and
could synergize with existing SPORE projects and cores. DF/HCC institutions match DRP funding from this
SPORE to expand the pool of DRP awardees. The DRP applications are judged for their potential as pilot or
collaborative studies that will generate feasibility data and for their ultimate potential to emerge as full projects
in future years of the SPORE program. The DRP employs a monitoring process to measure progress and
outcomes of DRP projects including the possible elevation of successful DRP awards to full projects. The
program is closely monitored through clearly established metrics and oversight by the DRP Awards
Committee. DRP awardees are required to present biannual progress reports.
胶质瘤孢子发育研究计划(DRP)的目标是确定创新的试点
神经胶质瘤的研究项目,具有转化潜力。DRP采用征求和审查程序
选择有价值的试验计划,以获得资助。招标过程利用了一个既定的、广泛的
丹娜-法伯/哈佛癌症中心(DF/HCC)的通信基础设施,以广泛传播年度
征求建议书(RFP)。审查过程利用了一组经验丰富的DF/HCC胶质瘤科学家。
DRP为具有最终转化潜力的创新项目提供有限期限的资金,
可以与现有的SPORE项目和核心协同工作。DF/HCC机构从这一点匹配DRP资金
SPORE以扩大DRP获奖者的人数。DRP应用程序根据其作为试点或
合作研究,将产生可行性数据,并为他们的最终潜力,成为完整的项目
在未来几年的SPORE计划中。DRP采用监控流程来衡量进度,
DRP项目的成果,包括可能将成功的DRP奖励提升为完整项目。的
通过明确建立的指标和DRP奖的监督,对该计划进行密切监控
以马克思DRP获奖者必须提交半年进度报告。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tracy T Batchelor其他文献
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling
纠正胶质母细胞瘤的药物开发范式需要连续组织采样
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Kirit Singh;K. Hotchkiss;I. Parney;J. D. de Groot;S. Sahebjam;N. Sanai;M. Plattén;E. Galanis;Michael Lim;P. Wen;G. Minniti;H. Colman;T. Cloughesy;M. Mehta;M. Geurts;I. Arrillaga;A. Desjardins;K. Tanner;S. Short;David F. Arons;Elizabeth S Duke;W. Wick;S. Bagley;D. Ashley;P. Kumthekar;R. Verhaak;A. Chalmers;Anoop P. Patel;Colin Watts;P. Fecci;Tracy T Batchelor;M. Weller;M. Vogelbaum;M. Preusser;Mitchel S. Berger;M. Khasraw - 通讯作者:
M. Khasraw
Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens
MTHFR 多态性与接受甲氨蝶呤方案治疗的原发性中枢神经系统淋巴瘤患者白质脑病风险的关联
- DOI:
10.1212/wnl.0000000000207670 - 发表时间:
2023 - 期刊:
- 影响因子:9.9
- 作者:
P. Karschnia;Sylvia C. Kurz;P. Brastianos;Sebastian F. Winter;A. Gordon;SooAe Jones;M. Pisapia;Naema Nayyar;J. Tonn;Tracy T Batchelor;S. Plotkin;J. Dietrich - 通讯作者:
J. Dietrich
Tracy T Batchelor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tracy T Batchelor', 18)}}的其他基金
Harvard/Stanford GTN Program: Novel targeted therapeutics for glioblastoma
哈佛/斯坦福 GTN 项目:胶质母细胞瘤的新型靶向疗法
- 批准号:
10306226 - 财政年份:2021
- 资助金额:
$ 8.36万 - 项目类别:
Harvard/Stanford GTN Program: Novel targeted therapeutics for glioblastoma
哈佛/斯坦福 GTN 项目:胶质母细胞瘤的新型靶向疗法
- 批准号:
10491787 - 财政年份:2021
- 资助金额:
$ 8.36万 - 项目类别:
Annual Meeting of the International Primary CNS Lymphoma Collaborative Group (IPCG)
国际原发性中枢神经系统淋巴瘤协作组(IPCG)年会
- 批准号:
10391991 - 财政年份:2021
- 资助金额:
$ 8.36万 - 项目类别:
Targeting metabolic vulnerabilities in Astrocytoma, IDH-mutant, Grade 4
针对星形细胞瘤、IDH 突变、4 级的代谢脆弱性
- 批准号:
10306229 - 财政年份:2021
- 资助金额:
$ 8.36万 - 项目类别:
Targeting metabolic vulnerabilities in Astrocytoma, IDH-mutant, Grade 4
针对星形细胞瘤、IDH 突变、4 级的代谢脆弱性
- 批准号:
10491830 - 财政年份:2021
- 资助金额:
$ 8.36万 - 项目类别:
相似海外基金
Nanocage-based systemic delivery of TGFβ trap for immunomodulation of brain neoplasms
基于 Nanocage 的 TGFβ 陷阱系统递送用于脑肿瘤的免疫调节
- 批准号:
10576313 - 财政年份:2021
- 资助金额:
$ 8.36万 - 项目类别:
Nanocage-based systemic delivery of TGFβ trap for immunomodulation of brain neoplasms
基于 Nanocage 的 TGFβ 陷阱系统递送用于脑肿瘤的免疫调节
- 批准号:
10399979 - 财政年份:2021
- 资助金额:
$ 8.36万 - 项目类别:
Experimental Analysis of Intracerebral Immunosurveillance Mechanism and Its Clinical Application to Management of Brain Neoplasms
脑内免疫监视机制的实验分析及其在脑肿瘤治疗中的临床应用
- 批准号:
09470295 - 财政年份:1997
- 资助金额:
$ 8.36万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Analysis of relationship between immunosurveillance and tumorigenesis in the brain and new approach to treatment of brain neoplasms
免疫监视与脑肿瘤发生关系分析及脑肿瘤治疗新途径
- 批准号:
07457316 - 财政年份:1995
- 资助金额:
$ 8.36万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Intracellular calcium signaling in malignant brain tumor cells and new application to the management of the brain neoplasms
恶性脑肿瘤细胞中的细胞内钙信号传导及其在脑肿瘤治疗中的新应用
- 批准号:
05454398 - 财政年份:1993
- 资助金额:
$ 8.36万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)